InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2025-07-16 00:00:00 ET · period of report 2025-07-14 · accession 0001437749-25-022862 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-07-16 2025-07-14 MNPR STARR CHRISTOPHER M Dir S - Sale+OE $40.00 -16.8K 5,173 -76% -$672.0K
D 2025-07-16 2025-07-14 MNPR STARR CHRISTOPHER M Dir X - OptEx $0.01 +16.8K 22.0K +325% +$168
D 2025-07-16 2025-07-14 MNPR STARR CHRISTOPHER M Dir X - OptEx $0.00 -16.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-07-14 S D 16,800 $40.00 5,173 D — — (F2) The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
2 Common Common Stock 2025-07-14 X A 16,800 $0.01 21,973 D — — (F1) This transaction involved a cash exercise of stock options.
3 Derivative Stock Options 2025-07-14 X D 16,800 $0.00 0 D $0.01 · — to 2026-04-04 16,800 Common Stock (F4) Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.